公开(公告)号：US20250108044A1

公开(公告)日：2025-04-03

申请号：US18791918

申请日：2024-08-01

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Cynthia Louise Harden ,  Gregory N. Beatch

IPC: A61K31/472 ,  A61K9/00 ,  A61P25/24

Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20240408075A1

公开(公告)日：2024-12-12

申请号：US18603554

申请日：2024-03-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： James Philip Johnson, JR.

IPC: A61K31/472 ,  A61K31/165 ,  A61K31/19 ,  A61K31/4015 ,  A61K31/41 ,  A61K31/4166 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering N44-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyll-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20240316033A1

公开(公告)日：2024-09-26

申请号：US18679045

申请日：2024-05-30

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. Beatch

IPC: A61K31/472 ,  A61K9/00 ,  A61P25/08

CPC classification number: A61K31/472 ,  A61K9/0053 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US12054486B2

公开(公告)日：2024-08-06

申请号：US17951640

申请日：2022-09-23

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Verner Alexander Lofstrand ,  Jung Yun Kim ,  Helen Clement ,  Kristen Nicole Burford ,  Paul Charifson ,  Shawn Johnstone ,  Juliette Sabbatani ,  Jan Felix Scholtes ,  Wei Zhang ,  Shaoyi Sun

IPC: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D487/04 ,  C07D491/052

CPC classification number: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D487/04 ,  C07D491/052

Abstract: The present disclosure is directed to compounds of formula (1):






wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

公开(公告)号：US11957675B2

公开(公告)日：2024-04-16

申请号：US17668340

申请日：2022-02-09

Applicant: XENON PHARMACEUTICALS INC.

Inventor： Simon Neil Pimstone

IPC: A61K31/472 ,  A61P25/24

CPC classification number: A61K31/472 ,  A61P25/24

Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20220193070A1

公开(公告)日：2022-06-23

申请号：US17532909

申请日：2021-11-22

Applicant: XENON PHARMACEUTICALS INC. ,  THE UNIVERSITY OF BRITISH COLUMBIA

Inventor： Robin Paul SHERRINGTON ,  Mary B. CONNOLLY

IPC: A61K31/495 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses of flunarizine, including for treating absence seizures in a human patient, such as absence seizures in childhood absence epilepsy (CAE), wherein the methods comprise administering (e.g., orally) to a patient in need thereof a therapeutically effective amount of flunarizine. The present disclosure is further directed to various improved methods of therapy and administration of flunarizine.

公开(公告)号：US11203572B2

公开(公告)日：2021-12-21

申请号：US17011355

申请日：2020-09-03

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Ivan William Hemeon ,  Steven McKerrall ,  Daniel Sutherlin

IPC: C07C381/10 ,  C07D401/12 ,  C07D205/04 ,  C07D211/22 ,  C07D211/42 ,  C07D213/69 ,  A61P25/04

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10745392B2

公开(公告)日：2020-08-18

申请号：US16440459

申请日：2019-06-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Kristen Nicole Burford ,  Thilo Focken ,  Verner Alexander Lofstrand ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/12 ,  A61P25/08 ,  C07D277/52 ,  C07D413/12

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20200157089A1

公开(公告)日：2020-05-21

申请号：US16556055

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/14 ,  C07D417/12 ,  C07D401/14 ,  C07D401/12 ,  C07D409/12 ,  C07D487/08 ,  C07D471/04 ,  C07D413/12

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20200071313A1

公开(公告)日：2020-03-05

申请号：US16555983

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson

IPC: C07D417/14 ,  C07D409/14 ,  C07D401/14 ,  A61P25/08 ,  C07C53/18

Abstract: This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.